Dynamic Technology Lab Private Ltd Grows Stock Position in Terns Pharmaceuticals, Inc. $TERN

Dynamic Technology Lab Private Ltd increased its position in shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) by 237.2% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 66,576 shares of the company’s stock after purchasing an additional 46,831 shares during the quarter. Dynamic Technology Lab Private Ltd owned approximately 0.08% of Terns Pharmaceuticals worth $500,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Engineers Gate Manager LP acquired a new stake in shares of Terns Pharmaceuticals in the second quarter valued at about $41,000. Canada Pension Plan Investment Board purchased a new stake in Terns Pharmaceuticals during the 2nd quarter valued at about $46,000. Velan Capital Investment Management LP grew its stake in Terns Pharmaceuticals by 17.6% during the 2nd quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company’s stock valued at $75,000 after acquiring an additional 3,000 shares in the last quarter. Cubist Systematic Strategies LLC raised its holdings in Terns Pharmaceuticals by 136.8% in the 1st quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company’s stock valued at $78,000 after acquiring an additional 16,363 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in Terns Pharmaceuticals in the 3rd quarter worth approximately $87,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on TERN. HC Wainwright boosted their target price on Terns Pharmaceuticals from $20.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Truist Financial lifted their price objective on Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Wall Street Zen raised Terns Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Barclays upped their target price on Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $58.11.

Insider Activity

In other Terns Pharmaceuticals news, insider Emil Kuriakose sold 1,155 shares of the business’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $38.57, for a total transaction of $44,548.35. Following the sale, the insider directly owned 50,365 shares in the company, valued at approximately $1,942,578.05. The trade was a 2.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Amy L. Burroughs sold 14,583 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $39.19, for a total value of $571,507.77. Following the completion of the sale, the chief executive officer owned 288,976 shares in the company, valued at approximately $11,324,969.44. This represents a 4.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 155,826 shares of company stock valued at $5,882,597 over the last three months. Company insiders own 1.50% of the company’s stock.

Terns Pharmaceuticals Price Performance

TERN stock opened at $45.29 on Wednesday. Terns Pharmaceuticals, Inc. has a 1 year low of $1.87 and a 1 year high of $48.26. The business’s 50-day moving average is $38.42 and its two-hundred day moving average is $25.56. The firm has a market capitalization of $4.70 billion, a P/E ratio of -43.97 and a beta of -0.31.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.